Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

  • Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19
  • MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage
  • Switzerland based Molecular Partners, a global leader in the development of DARPin …
/by

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

  • Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
    • Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
    • Sandoz …
/by

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

  • Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
    • Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
    • Sandoz …
/by

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 
  • Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the complement system’s alternative pathway, targeting the underlying cause of C3G.4–6
  • Data presented at the American Society of Nephrology (ASN) 2020 Annual Meeting shows that investigational iptacopan …
/by

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

  • Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases
  • IgA nephropathy (IgAN), while rare, is the most common form of glomerulonephritis, affecting mostly young adults with no approved treatment option and significant risk to progress to e …
/by

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)

  • Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and death

  • There are no approved disease modifying therapies that delay disease onset or slow progression of the disease

  • Branaplam (LMI070) is an orally administered, small molecule RNA splicing modulator that could potentially reduce the levels of mutant huntingtin protein

Basel, October …

/by
Sandoz appoints new Board representative to global AMR Industry Alliance
  • Dominic De Souza, global head of Anti-Infectives sustainability and AMR program, appointed to represent Sandoz on AMR Industry Alliance
  • Alliance brings together approximately 100 life science companies / associations in search of sustainable solutions to curb antimicrobial resistance (AMR)
  • Sandoz, as largest global provider of generic antibiotics, is committed to driving a pragmatic and balanced approach to tackling this growing global health threat

Holzkirchen, October 20, 2020 — Sandoz is pleased to announce the …

/by

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

  • If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1
  • Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2, and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread …
/by
Sandoz Donates 20 critically needed generic medicines to hospitals and dispensaries in continued support of the people of Beirut

In continued support of the people of Beirut, Lebanon impacted by the August 4 port explosion and the ongoing rebuilding efforts, Sandoz has donated 20 critically needed generic medicines through the non-governmental organization (NGO), Beit el Baraka.

The donations will be disbursed to severely damaged hospitals and also dispensaries in order to best respond to the ongoing devastation, and supports the initial monetary donation from Novartis to the Red Cross for early relief efforts.

Sandoz is thankful for the safety of our associates who live and work in Lebanon, and grateful …

/by